Biotech Fund Doubles Down: Scholar Rock Bet Drives 26% Rally
A major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
This overview covers the concept of automatic rebalancing, its purpose, and how it helps maintain target asset allocations with minimal effort.
5,552 articlesA major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
Wasatch Advisors dumped a large Trex stake, triggering a sharp move in Trex shares. This piece explains what happened...
Gold-backed GLD typically delivers a steadier path than silver-backed SLV across a decade. This guide explains why, w...
A major fund manager disclosed a sizable exit from a tactical commodity ETF, signaling a shift in market stance. This...
Biotech giants 2026 could offer a compelling mix of growth and stability for investors. This article dives into two p...
Smart investing isn’t about chasing the hottest story. It’s about owning durable businesses that quietly compound val...
A big move by an asset manager can ripple through a stock’s price and its story. This article explains what asset man...
A big-name investment fund backed an IoT stock with a $20 million stake last quarter. Since then, the stock has tumbl...
Oil prices are volatile, driven by geopolitics and supply dynamics. This guide looks at three ETFs that could shine i...
Midweek headlines can turn crypto markets on a dime. This piece explains the drivers behind bitcoin sinking wednesday...
Geopolitics are shaping energy markets in real time. A fresh disruption from Iran adds a new layer of risk and opport...
A biotech insider sale can spark questions about company momentum. This article digs into the Stoke Therapeutics CMO ...